SLC1A5 and gastric cancer: The ASCT2 competitive inhibitor benzylserine reduced the growth of some ASCT2-expressing gastric cancer cell lines, although the drug sensitivity of the cell lines was not necessarily associated with the level of ASCT2 expression [69].